IRIXHealthcare · Medical DevicesThe 1 Wall Street analysts covering IRIDEX Corp. hold a median 12-month price target of $2.75 — +206.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores IRIDEX Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Revisions (33): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IRIX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +206.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2024 | Stifel | Maintains | Hold | $2.00 |
| 15 May 2024 | Stifel | Maintains | Hold | — |
| 26 Aug 2022 | Stifel | Downgrade | Hold | — |
| 12 May 2021 | Roth Capital | Maintains | Buy | — |
| 3 Mar 2021 | Roth Capital | Maintains | Buy | — |
| 13 Jan 2021 | Roth Capital | Maintains | Buy | — |
| 12 May 2020 | Stifel | Maintains | Buy | — |
| 4 Jan 2019 | Stifel | Maintains | Buy | — |
| 4 Jan 2019 | Stifel Nicolaus | Maintains | Buy | — |
| 26 Oct 2018 | Stifel | Initiates | Buy | — |
| 26 Oct 2018 | Stifel Nicolaus | Initiates | Buy | — |
| 21 Dec 2016 | Roth Capital | Initiates | Buy | — |
| 26 Jan 2016 | Singular Research | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRIX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, IRIDEX Corp. returned −17.6% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 91% of US stocks
Cheaper than 29% of US stocks
Cheaper than 82% of US stocks
Higher than 18% of US stocks
Higher than 41% of US stocks
Higher than 25% of US stocks
Higher than 22% of US stocks
Higher than 17% of US stocks
Higher than 31% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IRIDEX Corp. has a market value of $11.9M and an enterprise value of $17.5M.
Revenue in the twelve months to 30 June 2026: $51.6M. The latest quarter shrank 7.4% year on year.
Net income over the same four quarters: −$3.5M, a −6.9% net margin.
Diluted earnings per share, trailing twelve months: $−0.20.
Free cash flow in the twelve months to 30 June 2026: −$2.0M.
Trailing P/E: −2.6×; forward P/E: 46.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
IRIDEX Corp. employs 93 people — $555K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IRIDEX Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
IRIDEX Corp. announced it has completed the relocation of its manufacturing facility to San Jose, California. The company expects to realize approximately $600,000 in annualized cost savings from the move.
Why it matters — The relocation to San Jose and the expected annualized cost savings indicate improved operational efficiency for IRIX.
IRIDEX reported a year-over-year widening loss per share in Q2, with revenues declining due to Middle East disruptions and reduced sell-through in China weighing on retina sales, though the Cyclo G6 product family continued to grow. The company's stock fell 15% following the report.
Why it matters — Investors tracking IRIDEX would care because the quarter shows ongoing headwinds in the retina segment that are offsetting progress in the Cyclo G6 product line.
IRIDEX Corporation held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's second-quarter financial results and business update for fiscal 2026.
Why it matters — IRIX watchers would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management commentary.
Iridex Corporation reported its financial results for the second quarter ended July 4, 2026, in a press release issued on August 18, 2026. The company, which provides laser-based medical systems for glaucoma and retinal disease treatment, disclosed its quarterly performance figures.
Why it matters — IRIX watchers would care because the report provides an update on the company's financial performance for the quarter, a key indicator of its business health.
Iridex Corporation announced it will release its second quarter 2026 financial results and provide a business update after the close of trading on August 18, 2026.
Why it matters — Investors tracking IRIX will learn the company's second-quarter 2026 performance and outlook when the results are published on August 18.
The 1 Wall Street analysts covering IRIDEX Corp. have a median 12-month price target of $2.75, with estimates ranging from $2.75 to $2.75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering IRIDEX Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IRIDEX Corp. 81 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, IRIDEX Corp. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +206.2% from the last close, and Ticker Nerd's factor model ranks IRIDEX Corp. 81 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering IRIDEX Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.75 to $2.75 over the next 12 months.
IRIDEX Corp. returned -17.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Iridex Corp. is an ophthalmic medical technology company that develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for eye care professionals.
The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Iridex Completes Relocation of Manufacturing Facility to San Jose, California". IRIDEX Corp. announced it has completed the relocation of its manufacturing facility to San Jose, California. The company expects to realize approximately $600,000 in annualized cost savings from the move.
Iridex Corp. is an ophthalmic medical technology company that develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for eye care professionals. The company’s products are used in the treatment of glaucoma, retinal disorders, diabetic eye disease, and other sight-threatening conditions, supporting both office-based procedures and surgical settings. Iridex’s portfolio includes laser consoles, delivery platforms, and single-use probes designed to work with its proprietary MicroPulse technology and other treatment systems. The company serves ophthalmologists, hospitals, surgical centers, research institutions, veterinary practices, and clinics through direct sales in the United States and distributor networks internationally. Headquartered in Mountain View, California, and founded in 1989, Iridex plays a specialized role in the medical device market by providing tools focused on precision ophthalmic therapy and recurring consumable use.
CEO Mr. Patrick Mercer · 93 employees · United States · https://www.iridex.com
